Search

CN-121971614-A - Application of ANKRD13A in preparation of intestinal cancer drugs and diagnostic reagents

CN121971614ACN 121971614 ACN121971614 ACN 121971614ACN-121971614-A

Abstract

The application provides application of ANKRD13A in preparation of medicines and diagnostic reagents for treating intestinal cancer, which relates to the technical field of biomedicine. The application confirms the close relation between ANKRD13A and intestinal cancer occurrence and development through a series of verification experiments, clinical sample analysis shows that the transcript abundance and the protein expression level of ANKRD13A in colon cancer tissues are obviously lower than those of normal colon tissues, cell level verification proves that the mRNA and the protein expression of ANKRD13A in colon cancer cell lines are obviously down-regulated compared with those of normal colon epithelial cell lines, animal experiments show that Ankrd a gene-deficient mice have higher colorectal tumor incidence rate and more tumor number under the induction of AOM/DSS, and tumor tissues show medium-high level canceration characteristics, along with abnormal beta-Catenin expression, nuclear translocation, ki67 positive cell increase and other malignant pathological manifestations. Together, the above experimental results demonstrate that lack of expression or down-regulation of ANKRD13A is closely related to increased risk of developing intestinal cancer.

Inventors

  • FAN YIHUI
  • ZHENG WEN
  • MAO RENFANG

Assignees

  • 南通大学

Dates

Publication Date
20260505
Application Date
20260116

Claims (9)

  1. Application of ANKRD13A as therapeutic target in preparing medicines for preventing and/or treating intestinal cancer.
  2. 2. The use of ANKRD13A as therapeutic target in the manufacture of a medicament for the prevention and/or treatment of intestinal cancer, wherein the intestinal cancer comprises colon cancer.
  3. Use of the ankrd13A gene, the protein encoded thereby, or a modulator against the ankrd13A gene and the protein encoded thereby for the preparation of a medicament for the prevention and/or treatment of intestinal cancer.
  4. 4. The ANKRD13A gene, the protein encoded thereby, or a modulator for the ANKRD13A gene and the protein encoded thereby, as claimed in claim 3, wherein the modulator comprises at least one of an agonist, an inhibitor, an antibody, and a nucleic acid molecule.
  5. 5. A medicament for treating intestinal cancer is characterized by comprising an agent for promoting ANKRD13A gene expression.
  6. 6. The agent for treating intestinal cancer according to claim 5, wherein the agent comprises one or more of ANKRD13A gene overexpression vector, ANKRD13A mRNA, promoter activator of ANKRD13A gene, small molecule compound capable of promoting transcription or translation of ANKRD13A gene, and recombinant viral vector carrying ANKRD13A gene.
  7. 7. The medicine for treating intestinal cancer according to claim 6, wherein the recombinant viral vector carrying ANKRD13A gene is an adenovirus vector or a lentiviral vector.
  8. 8. A medicament for the treatment of intestinal cancer according to claim 5, wherein the medicament further comprises pharmaceutically acceptable adjuvants.
  9. The application of ANKRD13A gene and its coded protein regulator in preparing medicine for diagnosing intestinal cancer.

Description

Application of ANKRD13A in preparation of intestinal cancer drugs and diagnostic reagents Technical Field The application relates to the technical field of biomedicine, in particular to application of ANKRD13A in preparation of intestinal cancer drugs and diagnostic reagents. Background Colorectal cancer is the third most common cancer worldwide, with an increased number of cases accounting for about 9.6% of all cancers, with mortality rates secondary (9.3%). 2022 data shows that the new onset of colorectal cancer (including anal cancer) is over 190 tens of thousands, and the death is about 90.4 tens of thousands. The disease distribution has obvious regional difference that the incidence rate of developed countries is about 3-4 times of that of developing countries, and the incidence rate of European, australian/New Zealand and North America is highest, and the incidence rate of rectal cancer is particularly prominent in east Asia. With the development of social economy, the incidence rate of regions such as eastern Europe, southeast Asia and south America is continuously rising, and the method has become a global important public health challenge. Currently, due to the high cost of colonoscopy and the widespread limited diagnostic and therapeutic infrastructure, there is a clinical need to develop non-invasive screening and diagnostic approaches to increase early discovery rates. In terms of treatment, although surgery and adjuvant chemotherapy have become routine strategies, a substantial proportion of patients experience relapse, e.g., about 16% of phase II patients and 40% of phase III patients develop disease progression post-operatively. Therefore, finding specific targets and developing novel targeted drugs to improve therapeutic effects have become urgent tasks for clinical research and practice. Disclosure of Invention The application aims to solve the technical problem of lack of specific targets aiming at colon cancer in the prior art. Based on the above object, the present application provides the following: the application of ANKRD13A as a therapeutic target in preparing medicines for preventing and/or treating intestinal cancer. Preferably, the bowel cancer comprises colon cancer. The application also provides application of the ANKRD13A gene, a protein coded by the ANKRD13A gene or a regulator aiming at the ANKRD13A gene and the protein coded by the ANKRD13A gene in preparing medicines for preventing and/or treating intestinal cancer. Preferably, the modulator comprises at least one of an agonist, an inhibitor, an antibody, a nucleic acid molecule. The application also provides a medicine for treating intestinal cancer, which is characterized by comprising an agent for promoting ANKRD13A gene expression. Preferably, the agent comprises one or more of an ANKRD13A gene overexpression vector, ANKRD13A mRNA, promoter activator of ANKRD13A gene, small molecule compound capable of promoting transcription or translation of ANKRD13A gene, recombinant viral vector carrying ANKRD13A gene. Preferably, the recombinant viral vector carrying the ANKRD13A gene is an adenovirus vector or a lentiviral vector. Preferably, the medicament further comprises a pharmaceutically acceptable adjuvant. The application also provides application of the ANKRD13A gene and a regulator of the protein coded by the same in preparing medicines for diagnosing intestinal cancer. Compared with the prior art, the application at least comprises the following beneficial effects By using ANKRD13A as a colorectal cancer occurrence related target, a preventive product containing an agent for promoting ANKRD13A gene expression is developed, so that the aim of reducing the occurrence risk of colorectal cancer related to colonitis is fulfilled. The purpose of specifically identifying colorectal cancer based on the difference between gene and protein expression is achieved by utilizing the ANKRD13A gene, the protein encoded by the ANKRD13A gene or the antibody and the nucleic acid molecule aiming at the ANKRD13A gene to prepare a diagnostic reagent, so that a convenient diagnostic tool is provided for clinic. By defining the key role of ANKRD13A in colorectal cancer occurrence, a targeted prevention product is developed, and the aims of reducing off-target effect in the colorectal cancer prevention process and improving the prevention specificity are achieved. The new function and application value of ANKRD13A in colorectal cancer are excavated, the research blank of the gene in the colorectal cancer diagnosis and treatment field is filled, and the aim of providing a brand new technical direction for colorectal cancer prevention and treatment is achieved. Drawings FIG. 1 is a view verifying down-regulation of ANKRD13A expression in colon cancer. A. mRNA expression of ANKRD13A in normal and colon cancer tissues, n=349, t=275. B. Based on mass spectral data of clinical proteome tumor analysis consortium, box plots of ANKRD13A protein abundan